D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research note issued on Friday,Benzinga reports. They presently have a $36.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on OMER. Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a report on Friday, June 27th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Omeros in a report on Friday, June 27th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Omeros Price Performance

OMER stock opened at $4.41 on Friday. The company has a market capitalization of $272.37 million, a price-to-earnings ratio of -2.09 and a beta of 2.26. Omeros has a 1-year low of $2.95 and a 1-year high of $13.60. The business has a 50 day simple moving average of $3.59 and a two-hundred day simple moving average of $5.77.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02. The firm had revenue of $28.60 million for the quarter, compared to analysts’ expectations of $0.31 million. Sell-side analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Trading of Omeros

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Harbour Investments Inc. raised its holdings in Omeros by 46.1% during the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 4,251 shares during the period. Tower Research Capital LLC TRC raised its holdings in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares during the period. Sei Investments Co. purchased a new stake in Omeros during the 2nd quarter valued at $40,000. Tower Research Capital LLC TRC raised its holdings in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,972 shares during the period. Finally, International Assets Investment Management LLC purchased a new stake in Omeros during the 2nd quarter valued at $47,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.